EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
The final trades of the day with the Fast Money traders.
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDIâ„¢for all indicationsmatching the reference product ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
J. Bradley White has been named managing partner of Osler, Hoskin & Harcourt LLP’s Ottawa office. He took the post on January ...
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.
Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the unanimous election of Michel Robidoux, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback